Citigroup Still Says Sell AbbVie
June 30, 2015 at 13:18 PM EDT
Is Wall Street underestimating the possible impact on AbbVie’s (ABBV) Humira from a generic version of the blockbuster drug? Citigroup analyst Andrew Baum and his team apparently think so. He reiterated the sell rating issued when the firm launched coverage of AbbVie back in February. Today’s note follows news late last week that Amgen (AMGN) [...]
